PMID- 36354732
OWN - NLM
STAT- MEDLINE
DCOM- 20221114
LR  - 20230112
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 29
IP  - 11
DP  - 2022 Nov 9
TI  - Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple 
      Myeloma.
PG  - 8529-8539
LID - 10.3390/curroncol29110672 [doi]
AB  - The prognosis of patients with multiple myeloma (MM) has improved dramatically 
      with the introduction of new therapeutic drugs, but the disease eventually 
      becomes drug-resistant, following an intractable and incurable course. A myeloma 
      niche (MM niche) develops in the bone marrow microenvironment and plays an 
      important role in the drug resistance mechanism of MM. In particular, adhesion 
      between MM cells and bone marrow stromal cells mediated by adhesion molecules 
      induces cell adhesion-mediated drug resistance (CAM-DR). Analyses of the role of 
      mitochondria in cancer cells, including MM cells, has revealed that the mechanism 
      leading to drug resistance involves exchange of mitochondria between cells 
      (mitochondrial transfer) via tunneling nanotubes (TNTs) within the MM niche. 
      Here, we describe the discovery of these drug resistance mechanisms and the 
      identification of promising therapeutic agents primarily targeting CAM-DR, 
      mitochondrial transfer, and TNTs.
FAU - Suzuki, Rikio
AU  - Suzuki R
AD  - Department of Hematology/Oncology, Tokai University School of Medicine, Isehara 
      259-1193, Japan.
FAU - Ogiya, Daisuke
AU  - Ogiya D
AD  - Department of Hematology/Oncology, Tokai University School of Medicine, Isehara 
      259-1193, Japan.
FAU - Ogawa, Yoshiaki
AU  - Ogawa Y
AD  - Department of Hematology/Oncology, Tokai University School of Medicine, Isehara 
      259-1193, Japan.
FAU - Kawada, Hiroshi
AU  - Kawada H
AD  - Department of Hematology/Oncology, Tokai University School of Medicine, Isehara 
      259-1193, Japan.
FAU - Ando, Kiyoshi
AU  - Ando K
AD  - Department of Hematology/Oncology, Tokai University School of Medicine, Isehara 
      259-1193, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221109
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
SB  - IM
MH  - Humans
MH  - *Multiple Myeloma/drug therapy
MH  - Cell Adhesion
MH  - Drug Resistance, Neoplasm
MH  - Mitochondria/metabolism
MH  - Tumor Microenvironment
PMC - PMC9689110
OTO - NOTNLM
OT  - CAM-DR
OT  - MM niche
OT  - mitochondrial transfer
OT  - multiple myeloma
OT  - tunneling nanotube
COIS- The authors declare no conflict of interest.
EDAT- 2022/11/11 06:00
MHDA- 2022/11/15 06:00
PMCR- 2022/11/09
CRDT- 2022/11/10 09:44
PHST- 2022/10/12 00:00 [received]
PHST- 2022/11/05 00:00 [revised]
PHST- 2022/11/07 00:00 [accepted]
PHST- 2022/11/10 09:44 [entrez]
PHST- 2022/11/11 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/11/09 00:00 [pmc-release]
AID - curroncol29110672 [pii]
AID - curroncol-29-00672 [pii]
AID - 10.3390/curroncol29110672 [doi]
PST - epublish
SO  - Curr Oncol. 2022 Nov 9;29(11):8529-8539. doi: 10.3390/curroncol29110672.